Preclinical COVID-19 developments | SARS-CoV-2 as a seasonal virus? | Focus on proteomics

May 28, 2020 -- Preclinical COVID-19 developments | SARS-CoV-2 as a seasonal virus? | Focus on proteomics

Preclinical COVID-19 developments | SARS-CoV-2 as a seasonal virus? | Focus on proteomics
Web Version
  Insights   |   Communities   |   Forums   |   Conferences   |   Rewards   |   More   May 28, 2020
Science Advisory Board
Top Stories
Bioimaging & Microscopy
Bioprocessing Sponsored by MilliporeSigma
Cancer & Disease Research
Cell Biology
Drug Discovery & Development
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Career Center

More Job Postings


Dear Science Advisory Board Member,

As the scientific community gains confidence in understanding the mechanisms by which SARS-CoV-2 has spread around the globe, many biopharmaceutical companies are moving forward with vaccine and therapy candidates.

A variety of companies have announced results from phase I clinical trials and preclinical development of COVID-19-related candidates. Researchers are supporting these efforts by developing innovative approaches to screening candidates and evaluating immune responses.

Meanwhile, Merck made several announcements this week that position it to be a player in the development of COVID-19 vaccines and therapies. The company's acquisition of Themis and its vaccine candidate could be a game changer for the biopharmaceutical company.

All this progress in drug development raises the question, will our efforts to control the SARS-CoV-2 virus be effective? Researchers explore the possibility of SARS-CoV-2 as an endemic seasonal coronavirus in a Journal of General Virology article.

In other science news, companies are focused on developing proteomics platforms. For instance, Thermo Fisher released a new line of proteomics analysis software. And Nautilus Biotechnology is developing a single-molecule sensitivity proteomics platform that it plans to bring to market.

Don't forget that we are hosting a webinar -- Grant Writing in the Age of Coronavirus -- later today (May 28) at 1 p.m. EDT. The event is free for members of the Science Advisory Board, and there is still time to register. If you have questions or want to learn how grant writing is changing due to the pandemic, I encourage you to attend.

Stay healthy and safe.

Samantha Black, PhD
The Science Advisory Board Editor

Members of The Science Advisory Board receive ViewPoints each and every time they share their opinions in one of our studies. ViewPoints can be redeemed for a wide variety of gifts in our catalog. Log in to the site now and see how many ViewPoints you have earned!
This email was sent by:
The Science Advisory Board | 671 N Glebe Rd #1610 Arlington, VA 22203, USA
If you would like to stop receiving emails from us, please click here to unsubscribe.
Facebook   Twitter   LinkedIn
© 2020 The Science Advisory Board | Contact Us | Privacy Policy

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter